FLJ22675_2010003K11Rik Inhibitors
FLJ22675_2010003K11Rik inhibitors encompass a variety of chemical compounds that interfere with distinct signaling pathways and cellular processes, potentially leading to the functional inhibition of this protein. Staurosporine, by targeting protein kinase C, could inhibit essential phosphorylation events that are necessary for FLJ22675_2010003K11Rik's activity. Similarly, compounds like LY294002 and wortmannin, throughtheir inhibition of the PI3K pathway, could decrease Akt-mediated phosphorylation and signaling, potentially affecting FLJ22675_2010003K11Rik if it is downstream of this pathway. Rapamycin, targeting mTOR, would likely inhibit FLJ22675_2010003K11Rik function if it's involved in mTOR-regulated growth pathways. MEK inhibitors like PD98059 and U0126 would impact FLJ22675_2010003K11Rik if it is modulated by the MAPK/ERK pathway, by preventing activation of this signaling cascade.
Furthermore, inhibitors such as SB203580, which targets p38 MAPK, and SP600125, which inhibits JNK, could decrease FLJ22675_2010003K11Rik activity by affecting stress response and apoptotic signaling pathways. PP2's inhibition of Src family kinases could lead to reduced FLJ22675_2010003K11Rik function if it is regulated by those kinases.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a broad-spectrum inhibitor of protein kinases. By inhibiting protein kinase C (PKC), it can prevent the phosphorylation of downstream proteins involved in cell proliferation and survival. If FLJ22675_2010003K11Rik requires phosphorylation for its activity, staurosporine could reduce FLJ22675_2010003K11Rik's function by preventing this modification. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K). By blocking PI3K, it leads to a decrease in Akt phosphorylation and activity. If FLJ22675_2010003K11Rik is downstream of Akt signaling, LY294002 would reduce FLJ22675_2010003K11Rik activity by decreasing Akt-mediated regulatory effects. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin specifically inhibits mTOR, a central protein in regulating cell growth and metabolism. If FLJ22675_2010003K11Rik is involved in mTOR-regulated pathways, rapamycin could inhibit its function by stalling processes that rely on mTOR signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of MEK1/2, enzymes upstream of ERK in the MAPK pathway. Inhibition here can alter cell cycle and growth. If FLJ22675_2010003K11Rik is influenced by the MAPK pathway, PD98059 would inhibit its function by reducing MAPK pathway activation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK, which is involved in response to stress and cytokines. If FLJ22675_2010003K11Rik is modulated by p38 MAPK, its function would be inhibited by SB203580 through reduction of p38 MAPK activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 prevents MEK1/2 activation, thereby inhibiting the downstream ERK pathway. If FLJ22675_2010003K11Rik's function is contingent on the ERK pathway, U0126 would inhibit it by blocking this pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor that acts irreversibly. An inhibition of PI3K activity, leading to reduced Akt signaling, would inhibit FLJ22675_2010003K11Rik if its activity is PI3K/Akt-dependent. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125 is a JNK inhibitor, affecting processes like apoptosis and inflammation. If FLJ22675_2010003K11Rik is regulated by JNK, SP600125 would inhibit its function by disrupting JNK signaling. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an inhibitor of Src family kinases, which are implicated in signaling pathways for cell proliferation and survival. Inhibition by PP2 could lead to a decrease in FLJ22675_2010003K11Rik activity if it is regulated by Src kinase signaling. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib inhibits the proteasome, thus preventing the degradation of proteins involved in cell cycle regulation. If the activity of FLJ22675_2010003K11Rik is controlled by proteasomal degradation, bortezomib could inhibit its function by altering protein turnover. | ||||||